Launching an IPO Involves Timing, Strategy

Even if you don't work for a company that is about to launch an initial public offering, the stock market can still be alluring as a personal investment opportunity. You know the science, so you should be able to pick the stocks, right? Not so fast, say the experts. No matter how good the science looks, market forces and poor management can drive a promising company--and its stock price--into the ground. Good management can make an average technology profitable, and poor management can make e

Written byJames Kling
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Even if you don't work for a company that is about to launch an initial public offering, the stock market can still be alluring as a personal investment opportunity. You know the science, so you should be able to pick the stocks, right? Not so fast, say the experts. No matter how good the science looks, market forces and poor management can drive a promising company--and its stock price--into the ground. Good management can make an average technology profitable, and poor management can make even the most stunning science look mediocre when it hits the marketplace. So when considering a company, see what you can find out about the history of its management and board. Have they built successful biotech companies before? Many executives have grown up along with the biotech industry and will sport a track record that could bode well for the stock. Keep an eye out for ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies